Merck KGaA will lay off 200 people between 2017 and 2022 as it revamps its European life sciences business, according to an article in BioPharmaDIVE. The company will reportedly relocate manufacturing to the cities of Darmstadt and Schnelldorf in Germany, Buchs in Switzerland and Molsheim in France, and will invest $102.5 million in the four sites.
Facilities in Germany's Steinheim, Eppelheim, Hohenbrunn and Berlin will be closed, which will result in layoffs for 200 people over the next five years. The company is aiming to centralize filling and distribution of small quantities of laboratory chemicals and reagents to speed up its response time for its customers, the story said.
Read the full article